At its meeting on 12 September 2022 the Transparency Council adopted position No. 87/2022 on the evaluation of the drug: Bimzelx (bimekizumab) under the drug programme “Treatment of moderate to severe plaque psoriasis (ICD-10: L40.0)”.
At its meeting on 12 September 2022 the Transparency Council adopted position No. 87/2022 on the evaluation of the drug: Bimzelx (bimekizumab) under the drug programme “Treatment of moderate to severe plaque psoriasis (ICD-10: L40.0)”.